GlassScriptPhysician profile
Kevin Gordon
NPI 1174815625
$3,070.40
in general payments reported to CMS, 2019-2025
26 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $279 · 2021: $437 · 2022: $238 · 2023: $241 · 2024: $425 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $835.06 | 2020-2025 | |
| Janssen Biotech, INC. | $548.53 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $216.77 | 2019-2025 | |
| Capsopro Services LLC | $200.00 | 2020 | |
| Celgene Corporation | $165.29 | 2021-2023 | Zeposia |
| Genzyme Corporation | $141.03 | 2023-2025 | |
| Gilead Sciences, INC. | $131.57 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $122.43 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.28 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $98.12 | 2019-2024 | Gattex, Entyvio |
| Amgen INC. | $97.85 | 2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $85.75 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $51.90 | 2021-2023 | |
| Digestive Care, INC. | $33.78 | 2024 | Pertzye |
| Evoke Pharma, INC. | $30.91 | 2023 | Gimoti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $29.10 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $25.88 | 2019-2021 | |
| Novo Nordisk INC | $23.80 | 2025 | Wegovy |
| Olympus America INC. | $19.43 | 2024 | Endoclot Phs |
| Lilly USA, LLC | $18.40 | 2025 | Omvoh |
| Qol Medical, LLC | $17.06 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.80 | 2021 | |
| Shionogi INC | $13.44 | 2019 | |
| Merck Sharp & Dohme LLC | $13.30 | 2023 | Zerbaxa, Dificid, Zinplava |
| Mauna Kea Technologies, INC. | $12.66 | 2024 | |
| Daiichi Sankyo INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.